outcome-specific prediction scores, such as ALARMEc, BASE-AF 2 , APPLE, CAAP-AF, and MB-LATER, were introduced. [15] [16] [17] [18] [19] [20] Recently, the prediction of mortality (2MACE) 21 or electro-anatomical substrate (DR-FLASH) 22 had been investigated (Table 1 ). Furthermore, it had been shown that electro-anatomical substrate measured during CA 22, 23 or through MRI, 9, 10 was associated with arrhythmia recurrences after CA in AF patients. 9, 22 Finally, blood biomarkers had become a promising tool for risk stratification and were included into several risk stratification tools (eg, ABC, [24] [25] [26] AEQ 27 ).
The aim of this review is to provide an overview of the most important clinical risk scores predicting rhythm outcomes, electroanatomical substrate, and mortality in AF patients undergoing CA for AF.
| SEARCH STRATEGY
Comprehensive electronic searches for relevant publications were performed in the PubMed database. For structural purposes, the literature research had been categorized according to different adverse events considered in this article. Major search terms were generated and combined with specific search terms for each event. The major search terms included "atrial fibrillation OR AF" AND "score OR risk OR index OR scheme OR ratio". As specific search terms the following list has been used: 1. AND "recurrence" 2. AND "LVA OR low voltage area OR substrate OR AF nest OR atrial foci OR atrial premature depolarization (APD)" 3. AND "death OR mortality" Studies were included when they reported the prediction of an outcome in AF patients using risk assessment tools. Two authors (F.K. and J.K.) screened all retrieved publications for qualifications by title and abstract screening and full text reviewing. By applying this search strategy, we considered a number of publications and clinical scores to be relevant references for this article.
3 | SCORES (TABLE 1) 3.1 | CHADS 2 /CHA 2 DS 2 -VASc Both scores had been originally developed for stroke prediction in AF patients. The CHADS 2 consisted of five variables: one point for congestive heart failure, hypertension, age ≥ 75, diabetes mellitus, and 2 points for previous stroke. 11 The scoring range is from 0 to 6 points.
The predictive value for different adverse events in AF patients was tested in several studies. Congestive heart failure, hypertension, age ≥ 75 (2 points), diabetes mellitus, previous stroke (2 points), vascular disease, age 65 to 74 years, and female sex were included to the CHA 2 DS 2 -VASc score. 12 The scoring range is from 0 to 9 points. 
| ALARMEc
The score was developed for the prediction of the arrhythmia recurrences after CA for AF, and ranges from 0 to 4 points 19 ; AF clinical type, left atrium size, renal insufficiency, metabolic syndrome, and cardiomyopathy were considered for the ALARMEc score (1 point each).
| BASE-AF 2
The BASE-AF 2 score was developed to predict recurrences in AF patients after cryoballoon ablation (CBA). 15 
| DR-FLASH
The DR-FLASH score was originally developed for the prediction of low voltage area (LVA). The clinical variables diabetes mellitus, renal dysfunction (assessed by using the Cockcroft-Gault formula), persistent form of AF, LA diameter > 45 mm, age > 65 years, female sex and hypertension were used in this score. Each variable scores 1 point, so the score's range is from 0 to 7 points. 22 
| CAAP-AF
This score was developed to predict AF freedom after CA and ranges from 0 to 13 points. 17 Coronary artery disease, left atrial diameter, age, presence of persistent, or long-standing AF, antiarrhythmics failed and female sex were included to CAAP-AF score. 
| MB-LATER

| ATLAS
Age > 60 years (1 point), type of AF-non-paroxysmal (2 points), indexed left atrial volume (1 point for each 10 mL/m 2 ) female sex (4 points) and current smoking (7 points) were detected as independent predictors for arrhythmia recurrences after CA and they were included in the ATLAS score. 28 3.9 | ABC death risk score Age, heart failure in the clinical history, N-terminal pro-B-type natriuretic peptide, troponin-T, and growth differentiation factor-15 levels were included in the ABC death risk score. 24 
| 2MACE
The 2MACE scoring ranges from 0 to 7 points and it is composed of 2 points each for metabolic syndrome and age > 75 years. The remaining variables (myocardial infarction [MI]/revascularization; congestive heart failure [EF < 40%] and thromboembolic events) are rated with 1 point each. 21 
| LAGO
Five clinical items had been included to the LAGO score: AF phenotype, structural heart disease, CHA 2 DS 2 -Vasc score < 1, LA diameter and LA sphericity. 29 Each item scores 1 point.
| RHYTHM OUTCOMES AFTER CATHETER ABLATION
Arrhythmia recurrences after medical treatment (invasive or pharmacological) can be categorized into early recurrences (ERAF), late recurrences (LRAF) or very late recurrences of AF (VRLAF). 11 ERAF is defined as any atrial tachyarrhythmia occurring within 3 months after index procedure, LRAF refers to the recurrences between 3 and 12 months post-CA, and VLRAF denotes any atrial tachyarrhythmia recurrence, which occurs after 12 months after index procedure.
We identified eight risk assessment tools that had been applied for prediction of arrhythmia recurrences after radiofrequency ablation (RFA) or CBA for AF: CHADS 2 , ALARMEc, BASE-AF 2 , CAAP-AF, APPLE, MB-LATER, ATLAS, and LAGO ( Table 2) .
Of note, there were substantial differences in the respective derivation cohort size among the scores. Generally, the scores developed in the large cohorts (eg, ATLAS, APPLE, and CAAP-AF) could have better generalizability than scores derived in smaller cohorts (ie, BASE-AF 2 , ALARMEc, MB-LATER), but each score would require further validation. Although an external validation is an important quality criterion of the risk stratification tools, it was not performed for every score. Indeed, the ALARMEc, APPLE, and MB-LATER scores were the only scores that had been validated in several external cohorts.
The recurrence prediction using well-known stroke risk scores (ie, the CHADS 2 , CHA 2 DS 2 -VASc, and R 2 CHADS 2 scores) has been tested in several studies. All three scores were compared to each other and showed only modest ability to predict the arrhythmia recurrence after CA for AF. 30 However, CHADS 2 , CHA 2 DS 2 -VASc, and R 2 CHADS 2 were inferior compared to scores originally developed for arrhythmia recurrence, such as the APPLE and MB-LATER scores, for example. 16, 18, 20, 31 Of note, most of the arrhythmia outcomes-specific scores were developed to predict the ERAF and/or LRAF after AF CA, while the BASE-AF 2 and MB-LATER scores use ERAF as a variable for the LRAF/VLRAF prediction and, therefore, cannot be used at baseline, before index CA. Finally, the simplicity and practicality of a score are very important factors for its clinical relevance. The use of clearly defined variables, such as LA size, sex, or AF type, and easy score calculation are basic necessities. Except for the ALARMEc score, which is based on a complex calculation, 32 the introduced scores are mainly feasible.
Of note, the BASE-AF 2 score had been developed in an AF cohort undergoing CBA. The reliability of this score in the recurrence prediction after RFA is not proven so far.
| CHADS 2
Chao et al 11 
| ALARMEc
The ALARMEc score has been developed in a cohort of 213 patients (73 RFA and 140 CBA patients). 14 was superior to CHADS 2 (AUC 0.533; P = 0.413) and CHA 2 DS 2 -VASc (AUC 0.519; P = 0.641). Furthermore, the same group of authors showed in a larger cohort of 911 patients with a longer follow-up of 60 months that patients with moderate and high ALARMEc strata benefited from multiple procedures or more extensive substrate modification. 32 Of note, there are also controversial data regarding ALAR-
MEc score showing that CBA should be avoided in patients with a high ALARMEc score (>2 points) because they have poor outcomes. 35 Interestingly, in another small study of 128 CBA patients, it was shown that a low ALARMEc score correlated with freedom from recurrent arrhythmia. 19 Although ALARMEc is the only study addressing prediction of recurrences both within 3 to 12 months and > 12 months, the results of this study are difficult to interpret because of non-standardized definitions of renal dysfunction and metabolic syndrome used in that study. 14, 36 
| BASE-AF 2
The BASE-AF 2 score has been developed in a cohort of 238 patients with a follow-up of 30 months (median 20 months) after CBA. . 15 A higher BASE-AF 2 score (≥3 points) was significantly associated with AF recurrences (HR 3.34, P = 0.001). Since ERAF is used as an independent predictor in this score, the BASE-AF 2 score cannot be used for baseline prediction, before index CA. Similar to the ALARMEc study, some variables included in the BASE-AF 2 score such as BMI were not in accordance with current definitions. 36, 37 Also, the unclear cut-off of AF duration >6 years complicates the assessment due to the fact that in some patients AF may begin with asymptomatic episodes.
| CAAP-AF
The CAAP-AF score has been developed in a large cohort of 1125 AF 
| APPLE
The APPLE score was originally developed to predict AF recurrences within the first year after CA. 16 The development cohort consisted of 1145 AF patients undergoing first CA. The predictive value of APPLE score was significantly superior to CHADS 2 and CHA 2 DS 2 -VASc on the ROC curve analysis (AUC 0.634 vs 0.538 and 0.542; P < 0.001, respectively). 16 Similar results (AUC 0.624, P < 0.001) were reported in an external validation cohort of 261 patients from the Vanderbilt University.
Moreover, the APPLE score has been shown to be useful for the prediction of rhythm outcome after repeat CA in The Leipzig Heart Center Ablation Registry. 20 Beside LVA prediction, the predictive value for LRAF had been analyzed. The APPLE score (OR 1.550; P < 0.001) was significantly associated with arrhythmia recurrence within 1 year after CA in the validation cohort. Of note, on multivariable analysis only the MB-LATER score (OR 1.747; P < 0.001) achieved slightly higher values within the validation cohort. 39 
| MB-LATER
The MB-LATER score has been introduced to predict VLRAF after RFA in 133 patients who were free from recurrent arrhythmia within first 12 months after CA. 18 After the development and internal validation (cohort of 39 patients), the score was compared to APPLE (AUC 0.716); BASE-AF 2 (AUC 0.648), ALARMEc (AUC 0.671), HATCH (AUC 0.582), CHADS 2 (AUC 0.555), and CHA 2 DS 2 -VASC (AUC 0.510) scores. 18 According to this comparison, MB-LATER showed better predictive accuracy for VLRAF (AUC 0.782, P < 0.001) than the other scores. Of note, the APPLE score (AUC 0.716, P = 0.002) showed almost similar prediction as the MB-LATER score. 18 Recently, two external MB-LATER score validation studies have been published. First, Deng et al used a Chinese cohort of >1400 patients. 31 They compared seven risk stratification scores (HATCH, Of note, APPLE score had been mentioned as an alternative to MB-LATER. 31 It is noteworthy that a score value of ≥2 of both MB-LATER (HR 1.52,P < 0.01) and APPLE score (HR 1.35, P < 0.01) has been significantly associated with an increased risk (52.1% and 35.3%, respectively) for AF recurrences. 31 The second external validation study had been performed by Potpara et al 38 MB-LATER showed the largest net benefit compared to the other scores 38 In ROC analysis. In addition, also as shown in Dengs study, the MB-LATER cut-off value of ≥2 had reached the highest predictive ability for LRAF. In both external validation cohorts ERAF, which has been included in the MB-LATER score, was shown to be an independent predictor for LRAF, which may partly explain the good predictive values of the MB-LATER. Interestingly, MB-LATER included male sex as a risk factor for recurrences in contrast to the CAAP-AF 17 and ATLAS 28 scores which included female sex as a risk factor. The MB-LATER score good predictive ability for VLRAF could be partly explained by higher AF prevalence in men. 40, 41 
| ATLAS
The ATLAS score has been developed in a cohort of 1934 AF patients undergoing first CA which were divided into a development and a validation cohort (50% each). 28 9 and was defined as any region with <0.5 mV 23 during electro-anatomical voltage mapping. Voltageguided substrate modification by targeting LVA in addition to circumferential pulmonary vein isolation (PVI) is more effective than conventional PVI ablation approaches concerning arrhythmia freedom after the ablation. [42] [43] [44] Recently, Yagishita et al showed that an LA voltage cut-off of <1.1 mV for electro-anatomic voltage mapping in sinus rhythm was an independent predictor for recurrences in patients without LVA (<0.5 mV). 45 Although LVA is an important risk factor for post-procedural AF, there are no standardized methods to predict LVA non-invasively before CA. 43, 44 The predictive ability of CHADS 2, DR-FLASH, APPLE, and MB-LATER for LVA are discussed in this section (Table 3 ).
| CHADS 2
Chao et al demonstrated that electrophysiological properties of the atrium differ between CHADS 2 strata, in a cohort of 247 patients with paroxysmal AF. In this study, the authors compared atrial voltage and total activation time of right and left atrium within CHADS 2 strata. 46 In this relatively small cohort, it could be demonstrated that a higher CHADS2 score (>3 pts.) is associated with LVA.
| DR-FLASH
The DR-FLASH score is currently the only score developed specifically for the prediction of LVA. The derivation cohort included 238 patients (153 with persistent AF). LVAs were found in 66 (28%) patients, and the score showed a good predictive ability for LVA with cut-off of 3 points (c-statistic 0.801; P < 0.001). The DR-FLASH score has been validated in an external cohort and showed similar results (AUC was 0.767, P < 0.001). Furthermore, DR-FLASH showed also a predictive ability for AF recurrence (1.3-fold increase per 1 point, P = 0.020) post-CA. Patients with LRAF had also a high DR-FLASH score (cut-off >3). 22 Of note, female sex-as a component of DR-FLASH score -was recently considered as a risk factor for AF substrate. Indeed, females have a 2-fold risk for LVA 47 and an almost 3-fold increased risk for AF recurrence following CA. 4 Females could present with clinical AF in a later stage of fibro-fatty infiltration, which could explain a higher presence of electro-anatomical substrate and worse rhythm outcomes after CA in female patients. 47 
| APPLE
Recently, it has been shown that the APPLE score-originally developed for arrhythmia recurrences-could be also used to predict LVA. 39 In a population of 214 patients, we showed that the APPLE score (OR 1.921, P < 0.001) and female sex (OR 2.283, P = 0.005) were independent predictors for LVA . 39 Interestingly, although atrial natriuretic peptide (NT-proANP) was an independent predictor on univariable analysis, there was no increase in the predictive value by adding NT-proANP to the APPLE score. Importantly, the APPLE score can be used for baseline prediction of recurrent AF post-CA and contribute to an individualized AF therapy. Its components such as an impaired ejection fraction (EF) and renal dysfunction were also associated with an electro-anatomical substrate. 48, 49 This correlation had also been shown in our recent study where the APPLE, DR-FLASH, and MB-LATER scores were compared regarding their predictive ability for LVA and recurrences. 50 First, we analyzed this prediction in the BioAF cohort of 214 AF patients and then validated the results in a retrospective cohort from The Leipzig
Heart Center AF Ablation Registry. While on univariable analysis all scores were significantly associated with LVA, on multivariable analysis only the APPLE (OR 1.789, P < 0.001) and DR-FLASH scores (OR 2.144, P < 0.001) remained significant predictors. However, the MB-LATER score (OR 1.445, P = 0.034) and ERAF (OR 5.078, P < 0.001), but not the APPLE score, were associated with LRAF on multivariable analysis. 50 All scores were significantly associated with recurrences, but ERAF was the most powerful predictor for later rhythm outcomes. In summary, on multivariable analysis the APPLE score was associated with prediction of both LVA and arrhythmia recurrences, whereas, as expected, DR-FLASH score ("a substrate score") showed the best prediction for LVA, but not for rhythm outcomes, and MB-LATER was significantly associated with rhythm outcomes, but not LVA.
| MACE AND DEATH
Several studies demonstrated that AF is associated with an increased risk of stroke, heart failure, or sudden cardiac death. 51, 52 Consequently, AF patients have a higher mortality rate compared to patients without AF regardless of gender and age. 51, 53 In addition, it had been demonstrated that an increased mortality rate in anticoagulated AF patients is mostly because of cardiovascular causes other than ischemic stroke. 54, 55 In this section, the CHADS 2 /CHA 2 DS 2 -VASc, ABC death risk score and the 2MACE score (Table 4 ) are discussed in terms of their relevance for death or major adverse cardiovascular events (MACE) prediction including fatal/non-fatal myocardial infarction, cardiac revascularization, and cardiovascular death.
| CHADS 2 /CHA 2 DS 2 -VASc
The value of CHA 2 DS 2 -VASc and CHADS 2 score for death and stroke prediction in AF patients after catheter ablation had been investigated by Chao et al 52 Both scores had been compared in a cohort of 565 AF patients. CHA 2 DS 2 -VASc score had been shown slightly better results (AUC 0.830) than the CHADS 2 score (AUC 0.785) in ROC analysis.
However, the difference between both curves did not reach significance (P = 0.116). 52 Both scores had been proven their ability to predict death and thromboembolic events in AF patients after CA. Similar findings had been published by Jacobs et al 34 in 2015. The predictive ability of CHA 2 DS 2 -VASc and CHADS 2 score for death and MACE after first CA had been investigated in a cohort of 2179 AF patients.
After FU of 5 years, it had been shown that CHA 2 DS 2 -VASc (HR 1.16; P = 0.04) and CHADS 2 (HR 1.30; P = 0.02) score were associated with MACE.
| 2MACE
The 2MACE score includes five clinical variables, and it has been developed for the prediction of major adverse cardiovascular events (MACE) in a derivation cohort of 1019 AF patients with oral AF patients who were treated with vitamin K antagonists. The cut-off value of 3 points in the 2MACE score showed the best combination of sensitivity and specificity to predict MACE, and the score (AUC 0.79; P < 0.001) was superior to CHADS 2 (AUC 0.660) and CHA 2 DS 2 -VASc (AUC 0.667). In an external validation cohort, the predictive ability of 2MACE score has been confirmed (AUC 0.66, P < 0.001). 21 Indeed, all three investigated scores (ie, the CHADS 2 , CHA 2 DS 2 -VASc, and 2MACE) showed similar ability for the prediction of MACE. In addition, it was shown that an optimal anticoagulation level also reduced the risk of MACE. 21 While number of participants within the study groups was relatively large, the incidence of MACE was only~180 out of 1.019 patients. Therefore, the predictive value of the 2MACE score needs to be validated in further studies.
| ABC death risk score
Recently, the ABC death risk score had been introduced to predict death in AF patients without CA treatment. 24 The development The ABC score was compared to CHA 2 DS 2 -VASc score in both cohorts and different subgroups. The ABC score showed a better predictive ability for mortality risk (AUC 0.75) than CHA 2 DS 2 -VASc (AUC 0.58) in all cohorts and subgroups.
Presently, these are the largest analyses using blood biomarkers (ie, cardiac troponin T, growth differentiation factor-15, and NT-proBNP) in AF patients. The usefulness of biomarkers as an important tool for risk prediction was also shown in several other studies. 7,56-59 AF causes endothelial damage, inflammation, and fibrosis, 5 and such atrial remodeling can be detected by specific biomarkers. 58 Furthermore, the predictive value of biomarkers of inflammation (CRP, IL-6), 60 myocardial damage (troponin), impaired cardiac function (BNP, ANP) or renal dysfunction (cystatin C) for adverse events in AF patients has been increasingly reported. 58 Natriuretic peptides, which were used in the ABC risk score, showed a good predictive ability for adverse events in AF patients, [60] [61] [62] whereas the results for Galectin 3 were conflicting. 56, 57, 63, 64 The role of biomarkers in AF treatment decision-making in daily clinical practice needs to be further elucidated.
| CONCLUSION AND FUTURE DIRECTIONS
The major purpose of this review article was to provide an overview of the current scores for diverse negative events in AF patients undergoing catheter ablation and to discuss them critically. The development of the "ideal score" for prediction negative outcomes in AF patients still remains a clinical unmet need. Therefore, choosing only one optimal scoring system seems impossible, regarding that all of the presented scores in this review have their strengths and limitations.
We therefore recommend to consider several important quality criterions for risk stratification scores: (a) size of development cohort, (Table 5) .
However, there are several scores useful for the prediction of at least one adverse outcome. While DR-FLASH and APPLE scores are useful for prediction of both LVA and recurrences, the MB-LATER and APPLE scores predict recurrences within first year after ablation as well as >12 months (very late outcomes). Nevertheless, further investigations are needed to develop a universal score for patients undergoing AF catheter ablation. Biomarkers as well as cardiovascular imaging could improve the existing scores leading to better predictive values.
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